Table 1 Main clinical characteristics of patients included in the study
Intermediate risk AML n=181 | |
|---|---|
Year of diagnosis (range) | 1994–2009 |
Gender n (%) | |
Male | 97 (54%) |
Female | 84 (46%) |
Median age, years (range) | 51 (18–69) |
Leukocyte count at diagnosis, × 109/l median (range) | 47 (1–408) |
FAB subtype (n) | |
M0 | 7 |
M1 | 53 |
M2 | 28 |
M4 | 48 |
M5 | 37 |
M6 | 6 |
M7 | 2 |
Cytogenetics n (%) | |
Normal | 131 (72%) |
Other intermediate-risk | 50 (28%) |
Molecular features n (%) | |
NPM1 mutation | 79 (43%) |
FLT3-ITD | 68 (37%) |
CEBPA biallelic mutation | 8 (7%) |
Therapeutic protocol (CETLAM group) | |
AML-94 | 9 (5%) |
AML-99 | 26 (14%) |
AML-03 | 146 (81%) |
Outcome | |
Complete response to induction regimen | 83% |
Overall survival (5- year) | 42±7% |
Leukemia-free survival (5- year) | 42±8% |
Cumulative incidence relapse (5- year) | 45±8% |
Allogeneic HSCT in first CR | 42 (23%) |
